Achieving that goal will be enhanced by data obtained with the results of 2 large (approximately 5,000) patient groups randomised to device or DOAC (CHAMPION-AF and CATALYST) (Table 10). Each study will focus on 1 device (Amulet or WATCHMAN FLX), both of which are approved and will include broader diverse groups of patients with multiple secondary analyses. In addition, OPTION will address LAAO and PVI. It must be kept in mind that during the 5 years of follow-up of these studies, new iterations of the devices will become available which may dramatically improve outcomes and render current issues less important. The goal of this technology will be to broaden the options available to the increasingly large number of patients with NVAF at risk for stroke.